Quick recap
Growth strategy focused on China's infant milk formula market
Full-year results show double-digit revenue and earnings growth
China sales up 38%, record market share in China label IMFMarketing investment up 13% to $260m boosts
China brand healthTotal IMF sales rise 8% despite market decline of 14%
China IMF market decline due to fewer newborns and increased competition
Revenue grows 10.1% to $1,592.9 million with varied regional sales
EBITDA up 11.8% to $219.3 million
NPAT up 26.2% to $144.8 million
Earnings per share rise 28.7% to 21.2 cents
Company expects growth in FY24 despite market challenges.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$8.04 |
Change
-0.230(2.78%) |
Mkt cap ! $5.850B | |||
| Open | High | Low | Value | Volume |
| $8.25 | $8.25 | $8.03 | $3.723M | 459.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 5123 | $8.04 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $8.05 | 17581 | 19 |
View Market Depth
| Last trade - 12.28pm 23/06/2025 (20 minute delay) ? |
| A2M (ASX) Chart |